.Pharmacolibrary.Drugs.ATC.D.D09AA02 .Pharmacolibrary.Drugs.ATC.D.D09AA02| name: | FusidicAcid |
| ATC code: | D09AA02 | route: | oral |
| n-compartments | 2 |
Fusidic acid is a steroidal antibiotic, primarily used for the treatment of infections caused by Staphylococcus species, including methicillin-resistant Staphylococcus aureus (MRSA). It is used both topically and systemically. Its main application is in skin infections, conjunctivitis, and occasionally for more severe systemic staphylococcal infections in combination with other antibacterials. Fusidic acid is approved and in use today in many countries, though its use for systemic infections is more restricted.
Pharmacokinetic parameters after a single 500 mg oral dose in healthy adult volunteers.
Bulitta, JB, et al., & Ambrose, PG (2013). Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrobial agents and chemotherapy 57(1) 498–507. DOI:10.1128/AAC.01354-12 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23147726
Marsot, A, et al., & Blin, O (2017). Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. British journal of clinical pharmacology 83(5) 1039–1047. DOI:10.1111/bcp.13178 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27813241
Marsot, A, et al., & Guilhaumou, R (2020). Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections. British journal of clinical pharmacology 86(11) 2319–2324. DOI:10.1111/bcp.14319 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32330996